Overview

Study Evaluate the PK Profile of Dalbavancin in Infants and Neonates Patients With Known or Suspected Bacterial Infection

Status:
Terminated
Trial end date:
2019-04-03
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the Pharmacokinetic (PK) profile of a single intravenous (IV) infusion dose of dalbavancin, and to evaluate the safety and tolerability of a single dalbavancin IV infusion.
Phase:
Phase 1
Details
Lead Sponsor:
Allergan
Treatments:
Dalbavancin
Teicoplanin